Recent

% | $
Quotes you view appear here for quick access.

Lexicon Pharmaceuticals, Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • pkornie@sbcglobal.net pkornie May 17, 2011 8:25 PM Flag

    Re: something_to_'o'_for.

    HOLDyoLEXG.OBfgoreverB.BuyGILDY.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • pkornie@sbcglobal.net pkornie May 17, 2011 8:29 PM Flag

      << At the bottom of a long dip is Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) which was trading in the $_.20 range at the beginning of the year and is currently trading in the $_.56 range, a decline of 29% in a little more than four months. LXRX is also very liquid. Its percentage of short sellers is average and the stock has also has positive, double digit EPS projections quarter over quarter. The company's drug candidates include LX1031, which has completed Phase II clinical trials for the treatment of irritable bowel syndrome and other gastrointestinal disorders; LX4211 that has completed Phase II clinical trials to treat type 2 diabetes; LX2931, which is in Phase II clinical trials for the treatment of rheumatoid arthritis and other autoimmune diseases; and LX1032 that has completed Phase II clinical trials to treat the symptoms associated with carcinoid syndrome. Lexicon Pharmaceuticals Inc is in the “Phase II Blues” but as these drugs move into Phase III trials, the stock will gain share valuation. Buying low at the base of bounce back could be very, very rewarding in the future. Rating :
      (2 Ratings)You have rated >> *


      .o.

      .

      • 1 Reply to pkornie
      • pkornie@sbcglobal.net pkornie May 27, 2011 1:26 AM Flag

        DoWa'u'WantIDO.

        << nutes ago 17-May-11 08:29 pm << At the bottom of a long dip is Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) which was trading in the $_.20 range at the beginning of the year and is currently trading in the $_.56 range, a decline of 29% in a little more than four months. LXRX is also very liquid. Its percentage of short sellers is average and the stock has also has positive, double digit EPS projections quarter over quarter. The company's drug candidates include LX1031, which has completed Phase II clinical trials for the treatment of irritable bowel syndrome and other gastrointestinal disorders; LX4211 that has completed Phase II clinical trials to treat type 2 diabetes; LX2931, which is in Phase II clinical trials for the treatment of rheumatoid arthritis and other autoimmune diseases; and LX1032 that has completed Phase II clinical trials to treat the symptoms associated with carcinoid syndrome. Lexicon Pharmaceuticals Inc is in the “Phase II Blues” but as these drugs move into Phase III trials, the stock will gain share valuation. Buying low at the base of bounce back could be very, very rewarding in the future. Rating :
        (2 Ratings)You have rated >> *


        .o.


        >>

        FN'o'.ByeBuy.

        .

 
LXRX
13.94-0.26(-1.83%)Aug 29 4:00 PMEDT